Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Allan Harris who wrote (2666)	10/14/2005 2:41:24 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4232

passive immunization with hyperimmune human IgG preparations should be the way to go, as the world deals with population density- and travel-related infectious threats. you can try to find prototype vaccines, and pay vounteers to donate plasma after vaccination. prison inmates were once used for this purpose, I believe. compensation systems existed to "incentivize" some plasma donors with hyperimmune titers in the early 90s, so we can certainly lean on some established expertise and capacity. a better source, and one that is certain to produce IgG against the correct target......... governments should immediately establish a RAPID RESPONSE program to tap survivors of any established viral threat? from this year's NABI 10-K........ We are not currently able to utilize the full capacity of our plasma fractionation facility. We began commercial manufacture of Nabi-HB at our Boca Raton biopharmaceutical manufacturing facility in the fourth quarter of 2001 and intend to expand the use this facility for the manufacture of polyclonal antibody products in our clinical product pipeline including, Altastaph and Civacir, and for the manufacture of products of other parties. For the foreseeable future, we may not utilize the full manufacturing capacity of the facility and there can be no assurance that we will ever operate the facility efficiently. There can be no assurance that we will have either our own products to manufacture or those of others to offset the cost of the facility’s operation. Further, we have limited experience manufacturing our clinical product candidates. Our failure to fully utilize the capacity of the plant or to manufacture products successfully could have a material adverse effect on our future business, financial condition and results of operations.